{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:21:34Z","timestamp":1791336094568,"version":"4.3.1"},"publisher-location":"Berlin, Heidelberg","reference-count":38,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642179686","type":"print"},{"value":"9783642179693","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011]]},"DOI":"10.1007\/978-3-642-17969-3_6","type":"book-chapter","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T11:32:33Z","timestamp":1308655953000},"page":"151-166","source":"Crossref","is-referenced-by-count":14,"title":["The GAF-Tandem Domain of Phosphodiesterase 5 as a Potential Drug Target"],"prefix":"10.1007","author":[{"given":"Joachim E.","family":"Schultz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Dunkern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Gawlitta-Gorka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Sorg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,6]]},"reference":[{"key":"6_CR1_6","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/S0968-0004(97)01148-1","volume":"22","author":"L Aravind","year":"1997","unstructured":"Aravind L, Ponting CP (1997) The GAF domain: an evolutionary link between diverse phototransducing proteins. Trends Biochem Sci 22:458\u2013459","journal-title":"Trends Biochem Sci"},{"key":"6_CR2_6","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.2174\/138161206778343046","volume":"12","author":"A Aversa","year":"2006","unstructured":"Aversa A, Bruzziches R, Pili M, Spera G (2006) Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 12:3467\u20133484","journal-title":"Curr Pharm Des"},{"key":"6_CR3_6","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrm911","volume":"3","author":"JA Beavo","year":"2002","unstructured":"Beavo JA, Brunton LL (2002) Cyclic nucleotide research \u2013 still expanding after half a century. Nat Rev Mol Cell Biol 3:710\u2013718","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6_CR4_6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488\u2013520","journal-title":"Pharmacol Rev"},{"key":"6_CR5_6","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S0026-895X(25)11184-X","volume":"13","author":"H Bergstrand","year":"1977","unstructured":"Bergstrand H, Kristoffersson J, Lundquist B, Schurmann A (1977) Effects of antiallergic agents, compound 48\/80, and some reference inhibitors on the activity of partially purified human lung tissue adenosine cyclic 3\u2032, 5\u2032-monophosphate and guanosine cyclic 3\u2032, 5\u2032-monophosphate phosphodiesterases. Mol Pharmacol 13:38\u201343","journal-title":"Mol Pharmacol"},{"key":"6_CR6_6","doi-asserted-by":"publisher","first-page":"19969","DOI":"10.1074\/jbc.M603374200","volume":"281","author":"S Bruder","year":"2006","unstructured":"Bruder S, Schultz A, Schultz JE (2006) Characterization of the tandem GAF domain of human phosphodiesterase 5 using a cyanobacterial adenylyl cyclase as a reporter enzyme. J Biol Chem 281:19969\u201319976","journal-title":"J Biol Chem"},{"key":"6_CR7_6","first-page":"225","volume":"7","author":"M Chasin","year":"1976","unstructured":"Chasin M, Harris DN (1976) Inhibitory and activators of cyclic nucleotide phosphodiesterase. Adv Cyclic Nucleotide Res 7:225\u2013264","journal-title":"Adv Cyclic Nucleotide Res"},{"key":"6_CR8_6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1006\/abio.1999.4100","volume":"271","author":"EB Cogan","year":"1999","unstructured":"Cogan EB, Birrell GB, Griffith OH (1999) A robotics-based automated assay for inorganic and organic phosphates. Anal Biochem 271:29\u201335","journal-title":"Anal Biochem"},{"key":"6_CR9_6","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.76.060305.150444","volume":"76","author":"M Conti","year":"2007","unstructured":"Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481\u2013511","journal-title":"Annu Rev Biochem"},{"key":"6_CR10_6","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1124\/mol.63.6.1364","volume":"63","author":"JD Corbin","year":"2003","unstructured":"Corbin JD, Blount MA, Weeks JL 2nd, Beasley A, Kuhn KP, Ho YS, Saidi LF, Hurley JH, Kotera J, Francis SH (2003) [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP. Mol Pharmacol 63:1364\u20131372","journal-title":"Mol Pharmacol"},{"key":"6_CR11_6","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1046\/j.1432-1327.2000.01297.x","volume":"267","author":"JD Corbin","year":"2000","unstructured":"Corbin JD, Turko IV, Beasley A, Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem 267:2760\u20132767","journal-title":"Eur J Biochem"},{"key":"6_CR12_6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2165\/00003495-200868030-00009","volume":"68","author":"KF Croom","year":"2008","unstructured":"Croom KF, Curran MP (2008) Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 68:383\u2013397","journal-title":"Drugs"},{"key":"6_CR13_6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6603(00)65001-8","volume":"65","author":"SH Francis","year":"2001","unstructured":"Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1\u201352","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"key":"6_CR14_6","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1074\/jbc.M511468200","volume":"281","author":"M Gross-Langenhoff","year":"2006","unstructured":"Gross-Langenhoff M, Hofbauer K, Weber J, Schultz A, Schultz JE (2006) cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281:2841\u20132846","journal-title":"J Biol Chem"},{"key":"6_CR15_6","doi-asserted-by":"publisher","first-page":"19657","DOI":"10.1074\/jbc.M800595200","volume":"283","author":"N Handa","year":"2008","unstructured":"Handa N, Mizohata E, Kishishita S, Toyama M, Morita S, Uchikubo-Kamo T, Akasaka R, Omori K, Kotera J, Terada T (2008) Crystal structure of the GAF-B domain from human phosphodiesterase 10A complexed with its ligand, cAMP. J Biol Chem 283:19657\u201319664","journal-title":"J Biol Chem"},{"key":"6_CR16_6","doi-asserted-by":"publisher","first-page":"25164","DOI":"10.1074\/jbc.M800230200","volume":"283","author":"K Hofbauer","year":"2008","unstructured":"Hofbauer K, Schultz A, Schultz JE (2008) Functional chimeras of the phosphodiesterase 5 and 10 tandem GAF domains. J Biol Chem 283:25164\u201325170","journal-title":"J Biol Chem"},{"key":"6_CR17_6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.tibs.2009.09.007","volume":"35","author":"MD Houslay","year":"2010","unstructured":"Houslay MD (2010) Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci 35:91\u2013100","journal-title":"Trends Biochem Sci"},{"key":"6_CR18_6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20021698","volume":"370","author":"MD Houslay","year":"2003","unstructured":"Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370:1\u201318","journal-title":"Biochem J"},{"key":"6_CR19_6","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1359-6446(05)03622-6","volume":"10","author":"MD Houslay","year":"2005","unstructured":"Houslay MD, Schafer P, Zhang KY (2005) Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503\u20131519","journal-title":"Drug Discov Today"},{"key":"6_CR20_6","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1093\/emboj\/cdf375","volume":"21","author":"T Kanacher","year":"2002","unstructured":"Kanacher T, Schultz A, Linder JU, Schultz JE (2002) A GAF-domain-regulated adenylyl cyclase from Anabaena is a self-activating cAMP switch. EMBO J 21:3672\u20133680","journal-title":"EMBO J"},{"key":"6_CR21_6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S0898-6568(01)00216-9","volume":"14","author":"L Liu","year":"2002","unstructured":"Liu L, Underwood T, Li H, Pamukcu R, Thompson WJ (2002) Specific cGMP binding by the cGMP binding domains of cGMP-binding cGMP specific phosphodiesterase. Cell Signal 14:45\u201351","journal-title":"Cell Signal"},{"key":"6_CR22_6","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.pharmthera.2005.07.003","volume":"109","author":"C Lugnier","year":"2006","unstructured":"Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109:366\u2013398","journal-title":"Pharmacol Ther"},{"key":"6_CR23_6","doi-asserted-by":"publisher","first-page":"3449","DOI":"10.1021\/jm040217u","volume":"48","author":"DT Manallack","year":"2005","unstructured":"Manallack DT, Hughes RA, Thompson PE (2005) The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J Med Chem 48:3449\u20133462","journal-title":"J Med Chem"},{"key":"6_CR24_6","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/nrd2058","volume":"5","author":"FS Menniti","year":"2006","unstructured":"Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5:660\u2013670","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR25_6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","volume":"100","author":"K Omori","year":"2007","unstructured":"Omori K, Kotera J (2007) Overview of PDEs and their regulation. Circ Res 100:309\u2013327","journal-title":"Circ Res"},{"key":"6_CR26_6","doi-asserted-by":"publisher","first-page":"18225","DOI":"10.1073\/pnas.0907635106","volume":"106","author":"J Pandit","year":"2009","unstructured":"Pandit J, Forman MD, Fennell KF, Dillman KS, Menniti FS (2009) Mechanism for the allosteric regulation of phosphodiesterase 2A deduced from the X-ray structure of a near full-length construct. Proc Natl Acad Sci USA 106:18225\u201318230","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR27_6","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.2174\/138161205774370799","volume":"11","author":"GM Rose","year":"2005","unstructured":"Rose GM, Hopper A, De Vivo M, Tehim A (2005) Phosphodiesterase inhibitors for cognitive enhancement. Curr Pharm Des 11:3329\u20133334","journal-title":"Curr Pharm Des"},{"key":"6_CR28_6","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrd893","volume":"1","author":"DP Rotella","year":"2002","unstructured":"Rotella DP (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1:674\u2013682","journal-title":"Nat Rev Drug Discov"},{"key":"6_CR29_6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/emboj\/cdg051","volume":"22","author":"SD Rybalkin","year":"2003","unstructured":"Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003a) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. EMBO J 22:469\u2013478","journal-title":"EMBO J"},{"key":"6_CR30_6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1161\/01.RES.0000087541.15600.2B","volume":"93","author":"SD Rybalkin","year":"2003","unstructured":"Rybalkin SD, Yan C, Bornfeldt KE, Beavo JA (2003b) Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ Res 93:280\u2013291","journal-title":"Circ Res"},{"key":"6_CR31_6","doi-asserted-by":"publisher","first-page":"16526","DOI":"10.1074\/jbc.271.28.16526","volume":"271","author":"C Sette","year":"1996","unstructured":"Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. J Biol Chem 271:16526\u201316534","journal-title":"J Biol Chem"},{"key":"6_CR32_6","doi-asserted-by":"crossref","first-page":"23802","DOI":"10.1016\/S0021-9258(18)54354-4","volume":"266","author":"SD Stroop","year":"1991","unstructured":"Stroop SD, Beavo JA (1991) Structure and function studies of the cGMP-stimulated phosphodiesterase. J Biol Chem 266:23802\u201323809","journal-title":"J Biol Chem"},{"key":"6_CR33_6","first-page":"3","volume":"20","author":"V Vasta","year":"2004","unstructured":"Vasta V, Beavo J (2004) Functions and pharmacological inhibitors of cyclic nucleotide phosphodiesterases. Cell Transm 20:3\u20138","journal-title":"Cell Transm"},{"key":"6_CR34_6","doi-asserted-by":"publisher","first-page":"5782","DOI":"10.1073\/pnas.0700279104","volume":"104","author":"H Wang","year":"2007","unstructured":"Wang H, Liu Y, Hou J, Zheng M, Robinson H, Ke H (2007) Structural insight into substrate specificity of phosphodiesterase 10. Proc Natl Acad Sci USA 104:5782\u20135787","journal-title":"Proc Natl Acad Sci USA"},{"key":"6_CR35_6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67\u201373","journal-title":"J Biomol Screen"},{"key":"6_CR36_6","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1517\/14728222.9.6.1283","volume":"9","author":"KY Zhang","year":"2005","unstructured":"Zhang KY, Ibrahim PN, Gillette S, Bollag G (2005) Phosphodiesterase-4 as a potential drug target. Expert Opin Ther Targets 9:1283\u20131305","journal-title":"Expert Opin Ther Targets"},{"key":"6_CR37_6","doi-asserted-by":"publisher","first-page":"12051","DOI":"10.1074\/jbc.M413611200","volume":"280","author":"R Zoraghi","year":"2005","unstructured":"Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280:12051\u201312063","journal-title":"J Biol Chem"},{"key":"6_CR38_6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1124\/mol.65.2.267","volume":"65","author":"R Zoraghi","year":"2004","unstructured":"Zoraghi R, Corbin JD, Francis SH (2004) Properties and functions of GAF domains in cyclic nucleotide phosphodiesterases and other proteins. Mol Pharmacol 65:267\u2013278","journal-title":"Mol Pharmacol"}],"container-title":["Handbook of Experimental Pharmacology","Phosphodiesterases as Drug Targets"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-17969-3_6.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T12:38:24Z","timestamp":1741264704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-17969-3_6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"ISBN":["9783642179686","9783642179693"],"references-count":38,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-17969-3_6","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}